Term: Drug Identification Number (DIN)

Printer friendly

Glossary Definition

Last Updated: 2009-03-09

Definition:

An eight digit number, assigned by the Therapeutic Products Directorate of Health Canada, to each drug approved for use in Canada in accordance with the Food and Drug Regulation. The same drug (e.g. Amoxicillin, 250 mg capsules) can have several different DINs associated with it (for example, due to different manufacturers, different dosage forms, routes or strengths).

Related concepts 

• Asthma - Measuring Prevalence
• Calculating Costs/Expenditures for Pharmaceuticals
• Costing Methods: An Overview of Costing Health Services in Manitoba
• Creating Drug Identification Number (DIN) Lists Using the SPD Server Updated DIN Master (UDM) File
• Diabetes - Measuring Prevalence
• Drug Classification Systems
• Hypertension - Measuring Prevalence
• Ischemic Heart Disease (IHD) / Coronary Heart Disease (CHD) - Measuring Prevalence
• Stroke - Measuring Prevalence

Related terms 

• Active Ingredient
• Antibiotic Use
• Antidepressants
• Antipsychotic Medications (children)
• Anxiolytic Medications
• Dosage Form
• Drug Classification Systems
• Drug Data Support Files
• Drug Identification Number (DIN) Master File
• Drug Product Database (DPD)
• Drug Program Information Network (DPIN)
• Formulary
• Master (Common) Formulary
• Narcotic Analgesic Medications
• Non-Steroidal Anti-Inflammatory Drug (NSAID)
• Number of Active Ingredients
• Psychostimulant Medications
• Route of Administration
• Strength

References 

• Lix L, Yogendran M, Burchill C, Metge C, McKeen N, Moore D, Bond R. Defining and Validating Chronic Diseases: An Administrative Data Approach. Winnipeg, MB: Manitoba Centre for Health Policy, 2006. [Report] [Summary] (View)

Term used in 

• Brownell M, Chartier M, Santos R, Ekuma O, Au W, Sarkar J, MacWilliam L, Burland E, Koseva I, Guenette W. How are Manitoba's Children Doing? Winnipeg, MB: Manitoba Centre for Health Policy, 2012. [Report] [Summary] [Updates and Errata] [Additional Materials] (View)
• Chateau D, Enns M, Ekuma O, Koseva I, McDougall C, Kulbaba C, Allegro E. Evaluation of the Manitoba IMPRxOVE Program. Winnipeg, MB: Manitoba Centre for Health Policy, 2015. [Report] [Summary] (View)
• Fransoo R, Martens P, Burland E, The Need to Know Team, Prior H, Burchill C. Manitoba RHA Indicators Atlas 2009. Winnipeg, MB: Manitoba Centre for Health Policy, 2009. [Report] [Summary] [Additional Materials] (View)
• Martens P, Fransoo R, The Need to Know Team, Burland E, Prior H, Burchill C, Romphf L, Chateau D, Bailly A, Ouelette C. What Works? A First Look at Evaluating Manitoba's Regional Health Programs and Policies at the Population Level. Winnipeg, MB: Manitoba Centre for Health Policy, 2008. [Report] [Summary] [Additional Materials] (View)
• Martens PJ, Bartlett J, Burland E, Prior H, Burchill C, Huq S, Romphf L, Sanguins J, Carter S, Bailly A. Profile of Metis Health Status and Healthcare Utilization in Manitoba: A Population-Based Study. Winnipeg, MB: Manitoba Centre for Health Policy, 2010. [Report] [Summary] [Updates and Errata] [Additional Materials] (View)
• Metge C, Black C, Peterson S, Kozyrskyj A, Roos NP, Bogdanovic B. Analysis of Patterns of Pharmaceutical Use in Manitoba, 1996: Key Findings - A POPULIS Project. Winnipeg, MB: Manitoba Centre for Health Policy and Evaluation, 1999. [Report] [Summary] (View)
• Metge C, Kozyrskyj A, Dahl M, Yogendran M, Roos NP. Pharmaceuticals: Focussing on Appropriate Utilization. Winnipeg, MB: Manitoba Centre for Health Policy, 2003. [Report] [Summary] (View)
• Metge C, Black C, Peterson S, Kozyrskyj AL. The population's use of pharmaceuticals. Med Care 1999;37(6 Suppl):JS42-JS59. [Abstract] (View)